Management of oxaliplatin-induced peripheral neuropathy

M Wasif Saif, John Reardon, M Wasif Saif, John Reardon

Abstract

Neurotoxicity is the most frequent dose-limiting toxicity of oxaliplatin. Acute sensory neurotoxicity manifests as rapid onset of cold-induced distal dysesthesia and/or paresthesia, sometimes accompanied by cold-dependent muscular contractions of the extremities or the jaw. The symptoms, often occurring during or shortly after infusion, are usually transient and mild. A cumulative sensory peripheral neuropathy may also develop with prolonged treatment with oxaliplatin, eventually causing superficial and deep sensory loss, sensory ataxia, and functional impairment. Studies have shown patients with acute sensory symptoms to display little or no axonal degeneration. The similarity of acute symptoms induced by oxaliplatin to those caused by several drugs or toxins acting on neuronal or muscular ion channels suggests that these symptoms may result from a specific interaction of oxaliplatin with voltage-gated sodium (Na(+)) channels. The current recommendations for the management of the acute and cumulative neurotoxicity from oxaliplatin include education about exposure to cold, dose modification, "stop and go", and use of neuromodulatory agents, in particular, intravenous calcium and magnesium infusion. Upon the approval of oxaliplatin-based regimens both for adjuvant and metastatic treatment of colon cancer, it is crucial to compile knowledge about the recognition and management of neurotoxicity from oxaliplatin.

Figures

Figure 1
Figure 1
Postulated mechanism underlying the pathogenesis of neurotoxicity caused by oxaliplatin. Na+ channelopathy: the theory that an oxalate affects the sodium channels has been entertained by other researchers as well. Oxalate is released intracellularly from oxaliplatin by bicarbonate ions. Oxalate and BAPTA, another calcium chelator, have produced effects on inward sodium currents in invertebrate models similar to those seen with oxaliplatin. Abbreviations: BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; DACH, 1,2-diaminocyclohexane.

References

    1. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Euro J Pharmacol. 2000;406:25–32.
    1. Agafitei RD, Schneider S, Iqbal S, et al. Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX) [abstract] J Clin Oncol. 2004;22:3600.
    1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.
    1. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A. 1999;96:4154–7.
    1. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984;44:4224–32.
    1. Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin: global safety in 682 patients [abstract] Proc Am Soc Clin Oncol. 1995;14:209.
    1. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol. 2002;16:3478–83.
    1. Cavaletti G, Bogliun G, Zincone A, et al. Neuro- and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res. 1998;18:3797–802.
    1. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001;37:2457–63.
    1. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:709–15.
    1. de Gramont A, Cervantes A, Andre T, et al. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol. 2004;22:3525.
    1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.
    1. Eckel F, Schmelz R, Adelsberger H, et al. Prevention of oxaliplatin neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr. 2003;127:78–82.
    1. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–61.
    1. Gedlicka C, Scheithauer W, Schüll B, et al. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 2002;20:3359–61.
    1. Gemlin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;5(Suppl 15):21–33.
    1. Goldberg R, Sargent D, Morton R, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
    1. Graham M, Lockwood G, Greenslade D, et al. Clinical pharmokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–18.
    1. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85:2293–7.
    1. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;4(Suppl 15):5–13.
    1. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol. 2002;21:129a.
    1. Grothey A, McLeod HL, Green EM, et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity [abstract] J Clin Oncol. 2005;23:3509.
    1. Hoff P, Pazdur R. Progress in the development of novel treatments for colorectal cancer. Oncology. 2004;18:705–8.
    1. Holmes J, Stanko J, Varchenko M, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in the Wistar rat model. Toxicol Sci. 1998;46:342–51.
    1. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077–82.
    1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8.
    1. Lajer H, Daugaard G. Cispaltin and hypomagnesemia. Cancer Treat Rev. 1999;25:47–58.
    1. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR) Ann Oncol. 2000;11:1477–83.
    1. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36(Suppl 2):S2–12.
    1. Maestri A, Pasquale Ceratti AD, Calandri C, et al. Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Am Soc Clin Oncol. 2002;21:247b.
    1. Mariani G, Garrone O, Granetto C, et al. Oxaliplatin induced neuropathy: Could gabapentin be the answer? Proc Am Soc Clin Oncol. 2000;19:609a.
    1. Marshall J, Zakari A, Hwang J, et al. Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy [abstract] J Clin Oncol. 2004;22:3670.
    1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–87.
    1. Midgley R, Kerr D. Colorectal cancer. Lancet. 1999;353:391–9.
    1. Neijt J, Engelholm S, Tuxen M, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084–92.
    1. Penz M, Kornek GV, Raderer M, et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol. 2001;12:421–2.
    1. Petrelli N, Douglas HO, Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7:1419–26.
    1. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407–18.
    1. Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res. 2004;4:576–82.
    1. Saltz L, Cox J, Blank C, et al. Irinotecan plus fluoruracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–14.
    1. Screnci D, McKeage M. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem. 1999;77:105–10.
    1. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol. 1993;11:909–13.
    1. Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002;94:2434–40.
    1. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:233–7.
    1. Wilson R, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–74.
    1. Wolmark M, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract] J Clin Oncol. 2005;23:3500.
    1. Wong GY, Michalak JC, Sloan JA, et al. Proceedings of ASCO, 2005: May 14-17. Orlando, FL, USA; 2005. A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study; p. 8001.
    1. Wu F, Takahashi M, Pegoraro E, et al. A new mutation in a family with cold-aggravated myotonia disrupts Na+ channel inactivation. Neurology. 2001;56:878–84.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa